Jan 27 (Reuters) - Akero Therapeutics (AKRO.O), opens new tab shares gained 117% in early trading on Monday, after its lead drug showed it can help patients with a type of liver disease to reverse ...
Akero Therapeutics reported Monday strong results from a nearly two-year, placebo-controlled study showing its drug efruxifermin reversed liver scarring in patients with cirrhosis caused by the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback